FiercePharma3d
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
oncnursingnews3d
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...
Hosted on MSN23y
What to Know About CDK4/6 Inhibitors as Breast Cancer Treatment: Weighing the Risks vs. Benefits
CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone ...
Novartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...
Seeking Alpha15d
Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Again, Jake, thanks so much for the time. Really appreciate it. I know we had a chance to catch up at ASCO. This year, you guys had a pretty big presence as you kind of rebooting Lilly Oncology. Maybe ...
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...